antitrypsin

an·ti·tryp·sin

(an'tē-trip'sin),
A substance that inhibits or prevents the action of trypsin.

antitrypsin

an·ti·tryp·sin

(an'tē-trip'sin)
A substance that blocks the action of trypsin.

antitrypsin

See ALPHA-ANTITRYPSIN.
References in periodicals archive ?
Arrowhead Pharmaceuticals announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority, or MEDSAFE, and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
A set of reagents for the quantitative determination of a1-antitrypsin; To determine antitrypsin, Glycated hemoglobin; To determine hemoglobin, Glycohemoglobin calibrator; To calibrate glycohemoglobin, Glycosylated hemoglobin (type 1) is the norm; For quality control, Glycosylated hemoglobin (type 2) pathology; For quality control
Under the exclusive license the company plans to conduct a Phase II study for the treatment of alpha-1 antitrypsin deficiency, a congenital orphan condition.
M2 PHARMA-August 23, 2017-Apic Bio to Advance Gene Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
Global Markets Direct's, 'Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2016', provides an overview of the Alpha- Antitrypsin Deficiency pipeline landscape.
USPRwire, Mon Oct 26 2015] Global Markets Direct's, 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2015', provides an overview of the Alpha- Antitrypsin Deficiency's therapeutic pipeline.
April 2, 2015--Using patient-derived stem cells known as induced pluripotent stem cells (iPSC) to study the genetic lung/liver disease called alpha-1 antitrypsin (AAT) deficiency, researchers have for the first time created a disease signature that may help explain how abnormal protein leads to liver disease.
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.
UKPRwire, Thu Aug 15 2013] Global Markets Direct's, 'Alpha - Antitrypsin Deficiency - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline.
After washing step, membrane was reacted with 1000-fold diluted goat anti-human alpha-1 antitrypsin polyclonal antibody, conjugated with HRP (Abcam) for 3 hr.
Recommendations for expensive treatments made for a genetic disorder called alpha-1 antitrypsin deficiency should be withdrawn because the drugs have no benefit, scientists said.
AAT is a replacement therapy in individuals who lack the Alpha-1 Antitrypsin protein.